Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: Results of Propensity score analyses1

Radiology

Volumn 269, Issue 2, 2013, Pages 603-611

  Choi, Gwang Hyeon ^a   Shim, Ju Hyun ^a   Kim, Min Joo ^a   Ryu, Min Hee ^a   Ryoo, Baek Yeol ^a   Kang, Yoon Koo ^a   Shin, Yong Moon ^a   Kim, Kang Mo ^a   Lim, Young Suk ^a   Lee, Han Chu ^a  

^a University of Ulsan   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CHEMOEMBOLIZATION; CHEMOLIPIODOLIZATION; COHORT ANALYSIS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HAZARD RATIO; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SKIN MANIFESTATION; STATISTICAL ANALYSIS; SURVIVAL TIME; TIME TO PROGRESSION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR INVASION; TUMOR THROMBUS;

EID: 84886643964     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13130150     Document Type: Article

References (33)

1. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020-1022.
2. Park K W, Park J W, Choi JI, et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2008;23(3):467-473. (Pubitemid 351342066)
3. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56(4):908-943.
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-390.
5. Cheng AL, Kang YK, Chen Z, et al. Effcacy and safety of sorafenib in patients in the Asia-Pacifc region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34.
6. Yoo DJ, Kim KM, Jin YJ, et al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? J Gastroenterol Hepatol 2011;26(1):145-154.
7. Kim KM, Kim JH, Park IS, et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 2009;24(5):806-814.
8. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and effcacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005;16(12):1653- 1659. (Pubitemid 44431162)
9. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and effcacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study. Cancer 1997;79(11):2087-2094. (Pubitemid 27227372)
10. Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011;18(2):413-420.
11. Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011;258(2):627-634.
12. Pinter M, Hucke F, Graziadei I, et al. Advancedstage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 2012;263(2):590-599.
13. Okusaka T, Okada S, Ishii H, et al. Prognosis of hepatocellular carcinoma patients with extrahepatic metastases. Hepatogastroenterology 1997;44(13):251-257. (Pubitemid 27096048)
14. Uka K, Aikata H, Takaki S, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007;13(3):414-420. (Pubitemid 46178976)
15. Shim JH, Park J W, Choi JI, Park BJ, Kim CM. Practical effcacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a hepatitis B virus-endemic area. J Cancer Res Clin Oncol 2009;135(4):617-625.
16. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drugeluting beads for hepatocellular carcinoma. J Clin Oncol 2011;29(30):3960-3967.
17. Park JW, Koh YH, Kim HB, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol 2012;56(6):1336-1342.
18. Kim SE, Lee HC, Kim KM, et al. Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. Korean J Hepatol 2011;17(2):113-119.
19. Kim JE, Ryoo BY, Ryu MH, et al. Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. Oncology 2012;82(2):119-125.
20. Shim JH, Lee HC, Kim SO, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012;262(2):708-718.
21. Lencioni R, Llovet JM. Modifed RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30(1):52-60.
22. Warr D, McKinney S, Tannock I. Infuence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol 1984;2(9):1040-1046. (Pubitemid 14026263)
23. Choi BI, Kim HC, Han JK, et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic fndings. Radiology 1992;182(3):709-713.
24. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RE-CIST) and modifed RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012;118(1):147-156.
25. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11(5):550-560. (Pubitemid 30660034)
26. Ridgeway G, McCaffrey D, Morral A. twang: toolkit for weighting and analysis of nonequivalent groups. R package version 1.0-2. http://cran. r-project.org/web/packages/twang/index.html. Published 2010. Accessed August 7, 2010.
27. Ho D, Imai K, King G, Stuart E. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 2011;42(8):1-28.
28. Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006;163(3):262-270. (Pubitemid 43145754)
29. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35(5):1164-1171. (Pubitemid 34454013)
30. Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. J Clin Oncol 2012;30(4 Suppl):LBA154.
31. Lerose R, Molinari R, Rocchi E, Manenti F, Villa E. Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer 2001;37(2):239-245. (Pubitemid 32144702)
32. Abou-Alfa GK. TACE and sorafenib: a good marriage? J Clin Oncol 2011;29(30):3949-3952.
33. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicineluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33(1):41-52.